Zytiga (abiraterone acetate) typically controls prostate cancer for roughly 6 to 25 months, depending on when in the disease course you start taking it. Patients with newly diagnosed, hormone-sensitive disease generally get longer benefit than those whose cancer has already become resistant to standard hormone therapy. The drug works by cutting off the testosterone supply that fuels prostate cancer growth, but the cancer eventually finds ways around this blockade in most men.
How Zytiga Works
Prostate cancer cells need androgens, particularly testosterone, to grow. Standard hormone therapy shuts down testosterone production in the testes, but the adrenal glands and even tumor cells themselves can still produce small amounts. Zytiga blocks a key enzyme involved in androgen production across all three sources: the testes, the adrenal glands, and the tumor tissue itself. It also blocks a second enzyme that converts precursor hormones into active androgens. The result is a more complete testosterone shutdown than standard hormone therapy alone.
Because Zytiga disrupts hormone pathways so broadly, it’s always taken alongside a low-dose steroid (prednisone) to prevent side effects from the resulting mineral imbalances in your body. The standard dose is 1,000 mg once daily.
Duration for Hormone-Sensitive Prostate Cancer
When Zytiga is started early, in men with newly diagnosed metastatic prostate cancer that still responds to hormone therapy, it delivers the longest benefit. In the landmark LATITUDE trial, men with high-risk disease who took Zytiga plus standard hormone therapy lived so much longer that researchers couldn’t even calculate a median overall survival for the treatment group during the study period. For comparison, the placebo group had a median survival of 34.7 months. That translates to a 38% reduction in the risk of death.
Many men in this setting stay on Zytiga for two years or longer before the cancer progresses. The earlier the drug is introduced, the more runway it tends to provide.
Duration for Castration-Resistant Prostate Cancer
Once prostate cancer stops responding to standard hormone therapy, it’s classified as castration-resistant. Zytiga still works at this stage, but for a shorter window. In clinical trials, the median time before the cancer showed signs of growing again on imaging was about 6.4 months. The median time before PSA levels started climbing again was about 9.2 months.
These are median figures, meaning half of patients did better and half did worse. Some men with castration-resistant disease stay on Zytiga for well over a year with good disease control, while others see progression within a few months.
When You’ll Know It’s Working
PSA (prostate-specific antigen) is the primary marker doctors use to track Zytiga’s effectiveness. Many patients see their first meaningful PSA drop within four weeks. A study of 274 patients found that a 30% PSA decline at the four-week mark was strongly predictive of longer-term benefit. Those men were nearly 12 times more likely to achieve a 50% or greater PSA reduction by 12 weeks, and they lived significantly longer on average (25.8 months versus 15.1 months for those without an early decline).
That said, expert guidelines recommend not making treatment decisions based on PSA changes earlier than 12 weeks after starting therapy. A slow initial response doesn’t necessarily mean the drug won’t work. Your doctor will likely check PSA at regular intervals and combine that information with imaging to get the full picture.
What Predicts a Longer Response
Not every patient gets the same mileage from Zytiga, and one emerging predictor is your baseline testosterone level before starting treatment. In a randomized trial comparing Zytiga to another hormonal therapy, men with the highest baseline testosterone levels had a median progression-free survival of 24.8 months on Zytiga, compared to just 10.7 months for those with the lowest levels. The survival difference was even more striking: 52.8 months versus 31.5 months. This effect was specific to Zytiga and wasn’t seen with the comparator drug, suggesting that higher residual testosterone at baseline may indicate a cancer that’s more dependent on the hormone pathway Zytiga blocks.
Other factors that generally predict a better response include lower disease volume at the time of starting treatment, fewer prior therapies, and a longer interval between the original diagnosis and the development of castration resistance.
Why Zytiga Eventually Stops Working
Nearly all prostate cancers eventually develop resistance to Zytiga. The cancer cells find alternative ways to activate the androgen receptor, the protein that drives their growth. Several mechanisms are at play.
The most studied is a shortened version of the androgen receptor called AR-V7. Normal androgen receptors have a binding site where testosterone attaches and switches them on. Zytiga works by eliminating testosterone so nothing can bind there. AR-V7 is missing that binding site entirely, yet it’s permanently switched on, driving cancer growth regardless of how low testosterone drops. Research shows that AR-V7 levels increase further after cancers progress on Zytiga, reinforcing its role in resistance. All currently approved hormonal therapies for prostate cancer target the binding site that AR-V7 lacks, which is why cross-resistance between these drugs is common.
Cancer cells can also amplify the androgen receptor gene, producing so many receptor copies that even trace amounts of remaining androgens are enough to fuel growth. Others develop mutations that allow the receptor to be activated by non-androgen hormones or even by the steroid (prednisone) taken alongside Zytiga.
Side Effects That May Affect Treatment Duration
Most patients tolerate Zytiga well enough to stay on it until the cancer progresses rather than stopping due to side effects. In clinical trials, fewer than 1% of patients discontinued the drug because of liver enzyme elevations, and similarly low rates stopped for heart-related problems. Your liver function will be monitored regularly, especially in the first few months.
The more common side effects stem from the drug’s broad effect on hormone pathways. About 28% of patients experience low potassium levels, 27% develop fluid retention or swelling, and 9% have elevated blood pressure. These are generally manageable with medication adjustments and monitoring rather than stopping Zytiga altogether. Fatigue and joint discomfort are also common but rarely treatment-limiting.